Ortho and pain management practice relies heavily on NSAIDs, but gastrointestinal side effects remain one of the most common reasons prescribers hesitate to use them long-term. Etoricoxib, manufactured by Servochem under the Koxitor range, was specifically developed to address this problem, and understanding exactly how it does so gives franchise partners a genuine clinical basis for representing the product.
Etoricoxib is a selective COX-2 inhibitor, meaning it targets cyclooxygenase-2, the specific enzyme responsible for producing the inflammatory prostaglandins involved in pain, swelling, and fever, while largely sparing cyclooxygenase-1, a related enzyme that plays a protective role in the stomach lining. Non-selective NSAIDs inhibit both COX-1 and COX-2 simultaneously, which is effective for pain relief but also increases the risk of ulceration and bleeding with extended use.
Clinical trials comparing Etoricoxib against non-selective NSAIDs like ibuprofen have found meaningfully lower rates of endoscopically detected ulcers with Etoricoxib, and studies measuring gastrointestinal microbleeding have found Etoricoxib performing comparably to placebo, while non-selective NSAIDs produced significantly more measurable blood loss. Etoricoxib was approved by India's Drugs Controller General in 2004, and has since been used across indications including osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and ankylosing spondylitis.
Selective COX-2 inhibitors as a category, including Etoricoxib, carry a documented cardiovascular consideration worth discussing directly with prescribers. Research comparing Etoricoxib to other COX-2 selective options has found it associated with a somewhat greater tendency to affect blood pressure control compared to some alternatives. This is not a reason to avoid representing the product, gastrointestinal risk reduction remains a genuine, clinically meaningful benefit, but it is worth being direct about the full picture.
Etoricoxib has a notably long elimination half-life, generally cited in the range of nineteen to thirty-two hours, which supports convenient once-daily dosing rather than the multiple-times-daily schedule some non-selective NSAIDs require.
Etoricoxib is not the only selective COX-2 inhibitor available, and franchise partners benefit from understanding how it compares to alternatives like celecoxib, which prescribers may already be familiar with. Research comparing these options has found broadly comparable efficacy across the class, but consistent differences in specific safety considerations, including the blood pressure effect noted with Etoricoxib specifically.
Osteoarthritis and other chronic ortho conditions typically require sustained, long-term anti-inflammatory management rather than short courses for acute injury. This extended treatment duration is precisely where the gastrointestinal safety distinction between selective and non-selective NSAIDs becomes clinically meaningful.
Before representing Koxitor to an orthopedic specialist for the first time, it is worth having the core mechanism explanation, selective COX-2 inhibition and its gastrointestinal safety rationale, ready to explain clearly. Servochem's team can provide additional clinical reference material to franchise partners building this kind of product fluency ahead of their first prescriber meetings.
Once-daily dosing genuinely reduces the practical burden on patients compared to multiple-times-daily regimens, and this convenience factor meaningfully affects whether a treatment plan actually succeeds outside the controlled conditions of a clinical trial. This is worth mentioning directly in prescriber conversations, since dosing convenience is a legitimate factor in treatment selection, not simply a secondary consideration behind pure pharmacological comparison.
Whether you are adding Koxitor to an existing ortho portfolio or building your first pain management category offering, Servochem's home page gives a full overview of the ortho and pain management range, and the tablets and capsules category covers the complete formulation lineup available to franchise partners.
Etoricoxib selectively inhibits COX-2 while largely sparing COX-1, which helps preserve the stomach's protective prostaglandins compared to non-selective NSAIDs.
Clinical trials have found meaningfully lower rates of endoscopically detected ulcers with Etoricoxib compared to non-selective NSAIDs like ibuprofen.
Etoricoxib is approved for osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and ankylosing spondylitis, among other indications.
Yes. Selective COX-2 inhibitors including Etoricoxib carry documented cardiovascular and blood pressure considerations worth discussing with prescribers.
Its long elimination half-life, generally nineteen to thirty-two hours, supports convenient once-daily dosing compared to more frequent NSAID schedules.
Yes. Every batch is manufactured under WHO-GMP certified conditions with documented quality checks at each stage of production.
After You Sign a PCD Franchise Agreement: What Actually Comes Next
Top Pharmaceutical Manufacturing Companies in India: What "Top" Should Actually Mean
Forjoint Explained: How Diacerein and Glucosamine Work Together
Ortho PCD Franchise in Chandigarh: A Franchise Partner's Guide
Building a Complete Ortho Pain Management Portfolio: A PCD Franchise Partner's Guide